ArticleDiscover oncology2025
Lablab purpureus bioactive fractions as potent anticancer agents: an in vitro and in Silico study.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundPlant-based bioactive compounds are essential for the discovery of drugs, especially in cancer research, because they include a wide range of chemicals and are very specific to certain types of cells. In earlier research, Lablab purpureus (LP), a legume rich in nutrients and with ethnomedicinal significance, showed encouraging antioxidant and anticancer potential. However, the specific bioactive components that cause these effects are still unknown. The objective of this study was to use a bioactivity-guided approach to isolate and characterise cytotoxic fractions from LP seed methanol extract, followed by in vitro and in silico evaluation.
methodsColumn chromatography and liquid-liquid partitioning were used to separate the fractions from the LP seed methanol extract. DPPH, FRAP, and ABTS assays were performed to determine the individual fractions with high antioxidant activity. Lablab Purpureus Methanol seed extract Methanol fraction (LPMMF 1.5), was hence subjected to MTT assay against MCF-7 and A549 cells for 24, 48, and 72 h. Further, dual AO/EtBr staining was performed to evaluate apoptosis induction. FTIR and HR-LCMS analyses were performed to identify the phytocompounds in LPMMF 1.5. The identified compounds were subjected to ADME screening, molecular docking, MM-GBSA, 500 ns molecular dynamics simulations, per-residue energy decomposition, and metadynamics to evaluate their stability in binding with cancer-specific targets (PARP1, CDK2, and CCNB1).
resultsLPMMF 1.5 had the most antioxidant activity and the strongest cytotoxicity of the tested fractions, with IC
conclusionsThis study identified LPMMF 1.5 as a bioactive fraction with significant antioxidant and anticancer activity. Picroside-1 emerged as a key compound, exhibiting strong affinity and stable interactions with cancer-relevant targets. These findings support its potential development as a plant-derived anticancer lead candidate.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.